top of page

All Posts


Welcome to the team Amelia!
Amelia Oszczyk is an Erasmus Master's student intern from the Jagiellonian University Collegium Medicum (Krakow, Poland). She will be working on the synthesis of MDM2-based PROTACs for selective degradation of mutant p53.

MedOrg Group
2 de mar.1 min de leitura


11-13 February 2026 - 16ENQO & 9ENQMB
Location: Lisboa, Portugal Program: https://16enqo-9enqmb.events.chemistry.pt/scientific-program Our project leader, Professor Maria Santos, shared our work through an oral communication entitled "Small molecules to reclaim tumor suppressor p53 function in cancer". Ricardo Ferreira and Tomás Ginestal shared our work through poster communications. All these communications highlight the most recent results of our project PROTAC4OncoP53. .

MedOrg Group
13 de fev.1 min de leitura


Tomás G. Monteiro won the Honourable Mention in the Portuguese Award for Best Master Thesis in Medicinal Chemistry & Chemical Biology 2025
We congratulate Tomás G. Monteiro, who was awarded at the 16ENQO & 9ENQMB with a Honourable Mention in the Portuguese Award for Best Master Thesis in Medicinal Chemistry & Chemical Biology 2025.

MedOrg Group
13 de fev.1 min de leitura


Habilitation Defense by Maria Santos Highlights Project Progress in Developing PROTACs for Mutant p53 Degradation
On Tuesday, 10 February, the coordinator of our project, M. M. M. Santos, successfully defended her Habilitation in Pharmacy, with specialization in Pharmaceutical Chemistry and Therapeutics, at the Faculty of Pharmacy, University of Lisbon. Her habilitation work, titled “Medicinal Chemistry Strategies for Developing p53‑Targeted Anti‑Cancer Therapeutics,” underscores her long‑standing commitment to advancing innovative therapeutic strategies against cancer. During the habili

MedOrg Group
10 de fev.1 min de leitura


Welcome to the team Francesco!
Francesco Napolitano joins the project as an Erasmus Intern at the MOC group from Università degli studi di Salerno (Salerno, Italy). He will be working in the synthesis of VHL-based PROTACs for selective mutant p53 degradation.

MedOrg Group
19 de jan.1 min de leitura


Maria M. Santos presents PROTAC4OncoP53 at the iMed.ULisboa Seminars
Maria M. Santos was invited to deliver a seminar at the iMed Seminars, where she presented the project “PROTAC4OncoP53”. During her talk, she highlighted the scientific rationale, key objectives, and recent progress of the project, which focuses on the development of innovative therapeutic strategies targeting p53 in oncology. The presentation fostered engaging discussion and knowledge exchange within the iMed community.

MedOrg Group
9 de dez. de 20251 min de leitura


Tomás G. Monteiro starts as Research Technician in the Project
In this tuesday (2 december 2025), Tomás G. Monteiro started a new position as Research Technician in the project. Tomás will support the technical management of the project, ensuring follow-up, results organization, and communication with the research team. Welcome to our team Tomás!

MedOrg Group
2 de dez. de 20251 min de leitura


Welcome to the team Alexandre!
Alexandre Charneca joins the project as a Master's student at the MOC group. He will be working in the synthesis of CRBN-based PROTACs for selective mutant p53 degradation.

MedOrg Group
2 de dez. de 20251 min de leitura


Best Poster Award- XIV Congresso AEFFUL
Location: Lisboa, Portugal Program: https://www.aefful.pt/congresso-aefful/ Tomás Monteiro shared his work through a poster titled "Exploiting Tryptophanol-derived Isoindolinones for PROTAC Development to Degrade Mutant p53 R273H and R280K" showcasing the first results of the PROTAC4OncoP53 project. Additionally, he won the Best Scientific Poster Award in the Master's students category.

MedOrg Group
15 de nov. de 20251 min de leitura


10-12 November 2025 - XXIX Encontro Luso-Galego de Química
Location: Braga, Portugal Program: https://xxixelgq.events.chemistry.pt/pt/programa Ricardo Ferreira shared his work through a talk titled "Chemical Strategies for Cancer Therapy: Targeted Degradation of Mutant p53 via PROTACs" showcasing the first results of the PROTAC4OncoP53 project.

MedOrg Group
14 de nov. de 20251 min de leitura
Research Technician Position Available
FARM-ID intends to hire a Research Technician within the scope of the research project reference LISBOA2030-FEDER-00735600 (Project No. 16199), entitled: “Proteolysis-targeting chimeric technology for the development of mutant p53-based anticancer drugs”, funded by national funds from the Portuguese Foundation for Science and Technology (FCT, LP.) and by the European Regional Development Fund (FEDER) through the Lisbon Regional Program Management Authority, for the developmen

MedOrg Group
13 de out. de 20251 min de leitura
Today the PROTAC4OncoP53 officially started!
The project will end in 2028.

MedOrg Group
15 de set. de 20251 min de leitura
bottom of page